Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Syngene International's Enterprise Value is ₹159,433 Mil.
Syngene International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4,597 Mil. Therefore, Syngene International's EV-to-EBIT ratio for today is 34.68.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Syngene International's Enterprise Value is ₹159,433 Mil.
Syngene International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9,126 Mil. Therefore, Syngene International's EV-to-EBITDA ratio for today is 17.47.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Syngene International (NSE:SYNGENE) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Syngene International's current Enterprise Value is ₹159,433 Mil.
Syngene International's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4,597 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Syngene International's EV-to-EBITDA for today is:
Syngene International's current Enterprise Value is ₹159,433 Mil.
Syngene International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹9,126 Mil.
Syngene International's current Enterprise Value is ₹159,433 Mil.
Syngene International's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹37,387 Mil.
Syngene International's current Enterprise Value is ₹159,433 Mil.
Syngene International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Syngene International's current Enterprise Value is ₹159,433 Mil.
Syngene International's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International Enterprise Value Related Terms
Syngene International Enterprise Value Historical Data
* Premium members only.
The historical data trend for Syngene International's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Syngene International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Syngene International's Enterprise Value falls into.
Syngene International Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Syngene International's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹159,433 Mil mean?
Syngene International (NSE:SYNGENE) has a Enterprise Value of ₹159,433 Mil as of Jul. 20, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Syngene International and its competitors.
Is Syngene International's Enterprise Value too high?
Syngene International's current Enterprise Value is ₹159,433 Mil. Overall, Syngene International has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Enterprise Value compare to TMO and DHR?
Syngene International's Enterprise Value of ₹159,433 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Syngene International and its competitors. Syngene International's current Enterprise Value is ₹159,433 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹770.19, compared to a current price of ₹417.60 — trading 45.8% below its estimated fair value. The current Enterprise Value is ₹159,433 Mil. Syngene International's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Enterprise Value is ₹159,433 Mil as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹417.60 is trading 45.8% below its estimated GF Value™ of ₹770.19.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
Enterprise Value: ₹159,433 Mil
GF Value™: ₹770.19 vs. price of ₹417.60 (45.8% below fair value)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
79GF Score
Get the complete analysis for NSE:SYNGENE
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
